|Post IPO Valuation|
|POST IPO FUNDING TOTAL||$34M|
|Post IPO Equity, 1/2013 ||$34M|
|Post IPO Debt, 2/2014 ||$65M|
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company’s pediatric products, designed to improve the health and well-being of children, are focused in the specific areas of allergy, upper respiratory, including nasal, chest congestion and cough, antibiotics and dermatology, including head lice, and contact dermatitis. The Company promotes its products through a sales and marketing organization with approximately 55 sales representatives, primarily in highly populated states, targeting pediatric and high-prescribing physicians that are in the top decile of physicians that prescribe its products. The Company’s current operating plan focuses on maximizing sales of its existing product portfolio. In addition, Pernix plans to accelerate growth by launching new products, line extensions, and new formulations and by acquiring and licensing approved products.